Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium
Pres. Biden recently warned about China's dominance when it comes to lithium demand, stating, "if we don't get moving, they're going to eat our lunch." One junior mining company in South America is looking to become a strong link in the lithium supply chain due to a monster acquisition.
Get the full scoop on this investment opportunity
Clay B. Siegall, insider at Seagen
Clay B. Siegall Insider Alerts

Get notified the next time Clay B. Siegall buys or sells Seagen stock. Enter your email address below to get our daily insider buying and selling report.

Clay B. Siegall Insider Information

CEO of Seagen

Dr. Clay Siegall serves as the president, CEO and chairman of Seattle Genetics, the biotechnology company he founded in 1997. 

The Washington-based company helps develop targeted cancer therapies to treat patients' unmet needs. Under Dr. Siegall’s leadership, Seattle Genetics has built a diverse flotilla of antibody-based cancer therapies, including ADCETRIS, which was granted accelerated FDA approval in 2011. 

Since 1997, Dr. Siegall has served as one of the company’s directors, and he assumed the role of president in 2000. In 2002, he became Seattle Genetics’ CEO, and he has been the board chairman since 2004. During his tenure, the company has raised more than $675 million through public and private offerings, and it went public in 2001. 

Prior to his career with Seattle Genetics, Dr. Siegall worked as a principal scientist at Bristol Myers Squibb Pharmaceutical Research Institute. From 1988 to 1991, he was a staff fellow and biotechnology fellow with the National Cancer Institute, National Institutes of Health. 

Dr. Siegall has received numerous awards and accolades for his contributions to the scientific community, including being recognized as the Ernst & Young’s Entrepreneur of the Year and the Puget Sound Business Journal’s Dealmaker of the Year. He has authored over 70 publications and holds 15 patents. 

Dr. Siegall currently serves on the boards of Mirna Therapeutics, Ultragenyx Pharmaceuticals and Alder Biopharmecuticals. He received his B.S. in zoology from the University of Maryland and his Ph.D. in genetics from George Washington University.

What is Clay B. Siegall's net worth?

The estimated net worth of Clay B. Siegall is at least $91.93 million as of December 3rd, 2015. Dr. Siegall owns 556,115 shares of Seagen stock worth more than $91,931,371 as of November 30th. This net worth estimate does not reflect any other investments that Dr. Siegall may own. Learn More.

What is Clay B. Siegall's salary?

As the CEO of Seagen Inc., Dr. Siegall earned a total compensation package of $16,493,557.00 in 2020. Dr. Siegall earned a salary of $1,043,651.00, stock awards of $9,295,156.00, options awards of $4,561,723.00, non-equity compensation of $1,575,900.00, and other compensation of $17,127.00.

How do I contact Clay B. Siegall?

The corporate mailing address for Dr. Siegall and other Seagen executives is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. Seagen can also be reached via phone at (425) 527-4000 and via email at [email protected]

Has Clay B. Siegall been buying or selling shares of Seagen?

Clay B. Siegall has not been actively trading shares of Seagen during the last ninety days. Most recently, Clay B. Siegall sold 35,706 shares of the business's stock in a transaction on Monday, August 30th. The shares were sold at an average price of $166.86, for a transaction totalling $5,957,903.16.

Who are Seagen's active insiders?

Seagen's insider roster includes Roger Dansey (Insider), Vaughn Himes (Insider), Jean Liu (EVP), Charles Romp (EVP), Clay Siegall (CEO), and Todd Simpson (CFO).

Are insiders buying or selling shares of Seagen?

In the last twelve months, insiders at the biotechnology company sold shares 38 times. They sold a total of 581,054 shares worth more than $93,266,658.34. The most recent insider tranaction occured on November, 11th when insider Vaughn B Himes sold 6,000 shares worth more than $1,071,780.00. Insiders at Seagen own 27.6 % of the company.

Information on this page was last updated on 11/11/2021.

Clay B. Siegall Insider Trading History at Seagen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/30/2021Sell35,706$166.86$5,957,903.16View SEC Filing Icon  
8/16/2021Sell2,789$154.55$431,039.95View SEC Filing Icon  
8/5/2021Sell23,560$163.08$3,842,164.80View SEC Filing Icon  
7/2/2021Sell15,268$156.36$2,387,304.48View SEC Filing Icon  
6/3/2021Sell29,353$144.51$4,241,802.03View SEC Filing Icon  
5/6/2021Sell29,353$134.97$3,961,774.41View SEC Filing Icon  
4/9/2021Sell12,602$141.96$1,788,979.92View SEC Filing Icon  
3/4/2021Sell29,353$145.74$4,277,906.22View SEC Filing Icon  
2/4/2021Sell29,353$165.57$4,859,976.21View SEC Filing Icon  
1/7/2021Sell29,353$172.44$5,061,631.32View SEC Filing Icon  
12/7/2020Sell15,723$181.14$2,848,064.22View SEC Filing Icon  
12/3/2020Sell21,253$179.28$3,810,237.84View SEC Filing Icon  
8/31/2020Sell14,351$155.69$2,234,307.19View SEC Filing Icon  
8/18/2020Sell27,060$158.17$4,280,080.20View SEC Filing Icon  
8/10/2020Sell28,475$156.74$4,463,171.50View SEC Filing Icon  
7/8/2020Sell28,472$175.08$4,984,877.76View SEC Filing Icon  
6/8/2020Sell28,472$148.77$4,235,779.44View SEC Filing Icon  
5/8/2020Sell28,472$161.01$4,584,276.72View SEC Filing Icon  
4/8/2020Sell28,472$120.01$3,416,924.72View SEC Filing Icon  
3/9/2020Sell28,472$110.09$3,134,482.48View SEC Filing Icon  
2/10/2020Sell28,472$114.61$3,263,175.92View SEC Filing Icon  
1/8/2020Sell28,472$111.32$3,169,503.04View SEC Filing Icon  
12/9/2019Sell28,472$114.56$3,261,752.32View SEC Filing Icon  
11/8/2019Sell28,472$107.61$3,063,871.92View SEC Filing Icon  
10/8/2019Sell28,472$82.47$2,348,085.84View SEC Filing Icon  
9/9/2019Sell28,472$68.33$1,945,491.76View SEC Filing Icon  
9/3/2019Sell9,693$70.80$686,264.40View SEC Filing Icon  
8/28/2019Sell28,951$73.21$2,119,502.71View SEC Filing Icon  
8/8/2019Sell20,149$76.52$1,541,801.48View SEC Filing Icon  
7/8/2019Sell20,148$66.89$1,347,699.72View SEC Filing Icon  
6/10/2019Sell20,148$69.05$1,391,219.40View SEC Filing Icon  
5/9/2019Sell20,148$68.06$1,371,272.88View SEC Filing Icon  
5/9/2019Sell4,824$67.43$325,282.32View SEC Filing Icon  
4/8/2019Sell20,148$79.22$1,596,124.56View SEC Filing Icon  
3/8/2019Sell20,148$69.19$1,394,040.12View SEC Filing Icon  
2/8/2019Sell20,148$65.17$1,313,045.16View SEC Filing Icon  
1/8/2019Sell20,148$65.73$1,324,328.04View SEC Filing Icon  
12/10/2018Sell20,148$59.74$1,203,641.52View SEC Filing Icon  
11/8/2018Sell20,148$61.54$1,239,907.92View SEC Filing Icon  
10/8/2018Sell20,148$77.39$1,559,253.72View SEC Filing Icon  
9/17/2018Sell20,148$76.84$1,548,172.32View SEC Filing Icon  
8/27/2018Sell25,514$74.23$1,893,904.22View SEC Filing Icon  
8/21/2018Sell25,000$74.95$1,873,750.00View SEC Filing Icon  
8/9/2018Sell18,831$72.71$1,369,202.01View SEC Filing Icon  
7/9/2018Sell18,832$69.07$1,300,726.24View SEC Filing Icon  
6/8/2018Sell18,832$65.12$1,226,339.84View SEC Filing Icon  
5/9/2018Sell18,832$54.97$1,035,195.04View SEC Filing Icon  
4/9/2018Sell18,832$50.52$951,392.64View SEC Filing Icon  
3/9/2018Sell18,832$57.32$1,079,450.24View SEC Filing Icon  
2/9/2018Sell18,832$49.75$936,892.00View SEC Filing Icon  
1/11/2018Sell18,832$51.71$973,802.72View SEC Filing Icon  
12/11/2017Sell18,832$55.40$1,043,292.80View SEC Filing Icon  
11/10/2017Sell18,832$58.00$1,092,256.00View SEC Filing Icon  
9/11/2017Sell18,832$53.49$1,007,323.68View SEC Filing Icon  
8/28/2017Sell25,506$47.89$1,221,482.34View SEC Filing Icon  
8/7/2017Sell10,413$48.91$509,299.83View SEC Filing Icon  
7/5/2017Sell10,423$51.98$541,787.54View SEC Filing Icon  
6/5/2017Sell10,423$65.21$679,683.83View SEC Filing Icon  
1/6/2017Sell14,465$57.89$837,378.85View SEC Filing Icon  
11/7/2016Sell14,465$58.43$845,189.95View SEC Filing Icon  
10/6/2016Sell14,465$54.41$787,040.65View SEC Filing Icon  
9/8/2016Sell31,269$50.08$1,565,951.52View SEC Filing Icon  
8/22/2016Sell23,381$46.59$1,089,320.79View SEC Filing Icon  
8/8/2016Sell11,660$47.19$550,235.40View SEC Filing Icon  
7/27/2016Sell4,042$45.20$182,698.40View SEC Filing Icon  
7/6/2016Sell7,618$40.56$308,986.08View SEC Filing Icon  
12/3/2015Sell3,720$39.99$148,762.80556,115View SEC Filing Icon  
11/4/2015Sell3,718$43.14$160,394.52643,588View SEC Filing Icon  
10/5/2015Sell3,718$41.30$153,553.40611,323View SEC Filing Icon  
9/3/2015Sell3,718$40.12$149,166.16611,323View SEC Filing Icon  
8/20/2015Sell31,754$42.02$1,334,303.08611,323View SEC Filing Icon  
See Full Table

Clay B. Siegall Buying and Selling Activity at Seagen

This chart shows Clay B. Siegall's buying and selling at Seagen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Seagen Company Overview

Seagen logo
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
Read More

Today's Range

Now: $165.31
Low: $164.82
High: $171.90

50 Day Range

MA: $174.03
Low: $161.34
High: $190.86

2 Week Range

Now: $165.31
Low: $133.20
High: $202.60

Volume

1,261,379 shs

Average Volume

888,440 shs

Market Capitalization

$30.23 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8
Get In On This Crisis Investment While You Can
The headline screamed "Amazon, Google and Netflix are fighting over this rare gas," which is helium, nonrenewable, and running out. When it's gone it's gone. That's a huge crisis for medicine, the military, and computer chips that run the 21st century's gadgets, appliances, and vehicles. But, a couple small companies have a solution.
Get a free report that shows you the crisis